World Library  
Flag as Inappropriate
Email this Article

Walter Fiers

Article Id: WHEBN0008066294
Reproduction Date:

Title: Walter Fiers  
Author: World Heritage Encyclopedia
Language: English
Subject: Vlaams Instituut voor Biotechnologie, Genomics, Genome, Gene, Bacteriophage
Publisher: World Heritage Encyclopedia

Walter Fiers

Walter Fiers

Walter Fiers (born 1931 in Ypres, West Flanders) is a Belgian molecular biologist.

He obtained a degree of Engineer for Chemistry and Agricultural Industries at the University of Ghent in 1954, and started his research career as an enzymologist in the laboratory of Laurent Vandendriessche in Ghent. In 1956-57, he worked with Heinz Holter in Copenhagen (Denmark). In 1960, he obtained a fellowship from the Rockefeller Foundation and joined the group of Bob Sinsheimer as a postdoc. At the California Institute of Technology Walter Fiers was exposed to Molecular Biology, which was then just developing, studying viral DNA. He demonstrated the physical, covalently closed circularity of Bacteriophage PhiX-174 DNA.[1] In 1962, Fiers moved to Madison, Wisconsin, to work in the laboratory of future Nobel laureate, Gobind Khorana.

At the end of 1962, Fiers returned to Belgium and set up the Laboratory of Molecular Biology at the University of Ghent. His research involved Bacteriophage MS2; he was the first to establish the complete nucleotide sequence of a gene (1972) and of a viral genome (bacteriophage MS2)(1976).[2][3] In 1978 Fiers and his team were the first to reveal the complete nucleotide-sequence of SV40.[4] The development of totally new procedures and knowledge led to the ability to clone almost any gene and to express these efficiently in bacteria or in other heterologous hosts.[5]

In 1997 Fiers retired and became Professor Emeritus, and the following year he retired from his position as director of the Laboratory of Molecular Biology. Together with Xavier Saelens and their team, he continued his research, to find a universal influenza vaccine, based on the M2 protein on the surface of the influenza A virus.[6][7] The ectodomain of the M2 protein remains unchanged in all human influenza viruses known, including the strains that caused the pandemics in the last century, which makes it eligible for a universal influenza A vaccine.[8][9][10]



  1. ^ Fiers, W., and R. L. Sinsheimer, The structure of the DNA of bacteriophage PhiX 174. III. Ultracentrifuge evidence for a ring structure, J. Mol. Biol. 5:424-434, 1962
  2. ^ Min Jou W, Haegeman G, Ysebaert M, Fiers W., Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein, Nature. 1972 May 12;237(5350):82-8
  3. ^ Fiers W, Contreras R, Duerinck F, Haegeman G, Iserentant D, Merregaert J, Min Jou W, Molemans F, Raeymaekers A, Van den Berghe A, Volckaert G, Ysebaert M., Complete nucleotide-sequence of bacteriophage MS2-RNA - primary and secondary structure of replicase gene, Nature, 260, 500-507, 1976
  4. ^ Fiers W, Contreras R, Haegemann G, Rogiers R, Van de Voorde A, Van Heuverswyn H, Van Herreweghe J, Volckaert G, Ysebaert M., Complete nucleotide-sequence of SV40 DNA, Nature, 273, 113-120, 1978
  5. ^ Remaut E et al., Plasmid vectors for high-efficiency expression controlled by the PL promoter of coliphage-lambda, Gene, 15, 81-93, 1981
  6. ^ Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W, A universal influenza A vaccine based on the extracellular domain of the M2 protein, Nat Med. 1999 Oct;5(10):1157-63
  7. ^ Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM, Soluble recombinant influenza vaccines, Philos Trans R Soc Lond B Biol Sci. 2001 December 29;356(1416):1961-3
  8. ^ Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, A universal human influenza A vaccine, Virus Res. 2004 Jul;103(1-2):173-6
  9. ^ De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W, Universal influenza A vaccine: optimization of M2-based constructs, Virology. 2005 June 20;337(1):149-61
  10. ^ De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W, The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection, Vaccine. 2006 January 30;24(5):544-51

See also

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Hawaii eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.